The main purpose of this study is to learn more about the safety and side effects of LY3471851 when given by injection just under the skin to participants with eczema. The study will last up to 48 weeks and may include up to 23 visits to the study center.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
48
Arkansas Research Trials, LLC
North Little Rock, Arkansas, United States
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline through Study Completion (up to Week 48)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3471851
PK: AUC of LY3471851
Time frame: Postdose on Day 1 through Day 14
PK: Trough Concentrations (Ctrough) of LY3471851
PK: Ctrough of LY3471851
Time frame: Week 12
PK: Maximum Concentration (Cmax) of LY3471851
PK: Cmax of LY3471851
Time frame: Postdose on Day 1 through Day 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
California Dermatology & Clinical Research Institute
Encinitas, California, United States
Center For Dermatology Clinical Research, Inc.
Fremont, California, United States
Therapeutics Clinical Research
San Diego, California, United States
Clinical Science Institute
Santa Monica, California, United States
Miami Dermatology and Laser Research
Miami, Florida, United States
ForCare Clinical Research
Tampa, Florida, United States
Medical Dermatology Specialists
Sandy Springs, Georgia, United States
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
Skin Sciences
Louisville, Kentucky, United States
...and 10 more locations